Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes

PURPOSE: To report the 52-week real-world efficacy and safety outcomes of brolucizumab therapy for neovascular age-related macular degeneration (nAMD) in Indian eyes. PATIENTS AND METHODS: A retrospective, multicentre chart analysis of 82 eyes of 82 patients with nAMD (switch therapy: 65 eyes; treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Debdulal, Maiti, Aniruddha, Sheth, Jay U, Mondal, Soumen, Boral, Subhendu, Nandi, Krishnendu, Sinha, Tushar Kanti, Das, Arnab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793787/
https://www.ncbi.nlm.nih.gov/pubmed/36583092
http://dx.doi.org/10.2147/OPTH.S395577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793787/
https://www.ncbi.nlm.nih.gov/pubmed/36583092
http://dx.doi.org/10.2147/OPTH.S395577

Ejemplares similares